Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

What’s Next for Gene Therapy in Cancer Treatment?

CPTx, a biotechnology company focused on innovative CAR T therapies, has announced key leadership changes aimed at advancing its groundbreaking work in gene therapy. Edward Rebar, PhD, has been appointed as the new Chief Scientific Officer, bringing over 30 years of experience in cell engineering and gene therapies. His expertise will help translate CPTx’s unique DNA vector technology into effective in vivo CAR T treatments, which could offer new hope for patients with cancer and autoimmune disorders.

This development is significant for anyone interested in the future of health and longevity. CAR T therapies are designed to harness the body’s immune system to fight diseases, particularly cancer. By improving the precision and effectiveness of these therapies, CPTx aims to provide more durable and adaptable treatment options. This could mean better outcomes for people battling serious health issues, as the technology allows for tailored treatments that can be adjusted based on individual needs.

The research is still in the early stages, with CPTx operating as a preclinical-stage company. While the potential for in vivo CAR T therapies is promising, it’s important to note that these treatments are not yet available to the public. The company is working to develop these therapies further before they can enter clinical trials, which are necessary to confirm their safety and effectiveness in humans.

For those interested in the future of health and wellness, keeping an eye on advancements in gene therapy and CAR T treatments could be worthwhile. While these therapies are not yet available, they represent a significant shift in how we might treat complex diseases in the future.

Source: globenewswire.com